Alzheimer's disease

Does Eli Lilly's Future Depend on its Alzheimer's Drug?
Motley Fool
Sat, 04/23/22 - 04:02 pm
Eli Lilly
Alzheimer's disease
donanemab
Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug
BioPharma Dive
Fri, 04/22/22 - 10:49 am
Biogen
Aduhelm
Europe
Alzheimer's disease
Cassava Faces Renewed Speculation Over Experimental Alzheimer’s Drug
BioSpace
Tue, 04/19/22 - 11:44 pm
Cassava Sciences
Alzheimer's disease
simufilam
A potential target for Alzheimer's treatment? Researchers unearth new immune response pathway
Endpoints
Mon, 04/18/22 - 11:53 pm
drug development
R&D
Alzheimer's disease
The next battle in the never-ending war over Aduhelm
Stat
Fri, 04/15/22 - 01:50 pm
Biogen
Aduhelm
Medicare
CMS
Eli Lilly
Alzheimer's disease
Alzheimer's biotech Alzheon nets $50M Series D
Endpoints
Thu, 04/14/22 - 10:53 am
Alzheon
funding
Alzheimer's disease
ALZ-801
How CMS independence is at the forefront of its Alzheimer's drug coverage decision
Endpoints
Mon, 04/11/22 - 10:34 am
CMS
Medicare
Biogen
Aduhelm
Alzheimer's disease
With Aduhelm slapped down by CMS, what's next for Biogen?
Fierce Pharma
Fri, 04/8/22 - 10:29 am
Biogen
Aduhelm
Medicare
Alzheimer's disease
CMS finalizes restrictions on Biogen's Alzheimer's drug coverage, will only fund use in clinical trials
Endpoints
Thu, 04/7/22 - 06:13 pm
Biogen
Aduhelm
CMS
Alzheimer's disease
clinical trials
Medicare
20 years in, Genentech persists and perseveres in Alzheimer's with gantenerumab
Fierce Biotech
Wed, 04/6/22 - 07:44 pm
Roche
Genentech
Alzheimer's disease
gantenerumab
'About as true as saying the earth is flat': Alzheimer's expert picks apart Biogen's Aduhelm manuscript
Endpoints
Mon, 04/4/22 - 11:22 pm
Biogen
Aduhelm
Alzheimer's disease
Sage's phase 2 Alzheimer's drug shows signs of cognitive improvement—but there's a catch
Fierce Biotech
Fri, 04/1/22 - 10:47 am
SAGE Therapeutics
SAGE-718
Alzheimer's disease
clinical trials
Biogen Submits Final Plan for Confirmatory Aduhelm Trial
BioSpace
Thu, 03/31/22 - 10:14 am
Biogen
Aduhelm
clinical trials
Alzheimer's disease
Biogen, Eisai unveil new data on lecanemab, but questions linger on ARIA-E; Spatial biology outfit grabs $33M round
Endpoints
Tue, 03/22/22 - 11:19 pm
Eisai
Biogen
lecanemab
Alzheimer's disease
Scoop: Biogen will finally publish its PhIII results for Aduhelm
Endpoints
Wed, 03/16/22 - 10:22 am
Biogen
Aduhelm
Alzheimer's disease
Eisai hands off responsibility for Aduhelm to Biogen
Pharmaforum
Tue, 03/15/22 - 11:43 am
Eisai
Biogen
Aduhelm
Alzheimer's disease
Alzheimer's patient groups pressure U.S. to pay for Biogen drug
Reuters
Sun, 03/13/22 - 11:07 pm
Alzheimer's disease
Biogen
Aduhelm
patient groups
A trio of amyloid-targeted Alzheimer's drugs will soon see key results, but an analyst predicts only 50-50 odds for one
Endpoints
Wed, 03/9/22 - 11:09 pm
Alzheimer's disease
clinical trials
Roche
Eli Lilly
Biogen
donanemab
lecanemab
gantenerumab
Small biotech CEO exodus continues as vTv, a troubled former Alzheimer's player, sees chief leave after just 4 months
Endpoints
Fri, 03/4/22 - 10:09 am
biotech
vTv Therapeutics
Alzheimer's disease
Roche starts new four-year trial of Alzheimer’s drug gantenerumab
Pharmaforum
Fri, 03/4/22 - 09:48 am
Roche
Alzheimer's disease
clinical trials
gantenerumab

Pages